✉ Email this page to a colleague
« Back to Dashboard
▶ Start for $1
Remove trial restrictions
Givinostat is an investigational drug.
There have been 14 clinical trials for Givinostat. The most recent clinical trial was a Phase 2 trial, which was initiated on June 1st 2017.
The most common disease conditions in clinical trials are Muscular Dystrophies, Muscular Dystrophy, Duchenne, and Arthritis, Juvenile. The leading clinical trial sponsors are Italfarmaco, Parexel, and inVentiv Health Clinical.
There are two hundred and sixty-five US patents protecting this investigational drug and two international patents.
Recent Clinical Trials for Givinostat
|Perpetrator DDI Potential of Givinostat as Inhibitor and Inducer of CYP3A and P-gp Activity||Italfarmaco||Phase 1|
|Placebo-Corrected Effects of Therapeutic Dose (100 mg) and Supratherapeutic Dose (300 mg) of ITF2357 (Givinostat) and Moxifloxacin on QT/QTC Interval||Italfarmaco||Phase 1|
|Clinical Study to Evaluate the Efficacy and Safety of Givinostat in Ambulant Patients With Becker Muscular Dystrophy||Italfarmaco||Phase 2|
Top disease conditions for Givinostat
Top clinical trial sponsors for Givinostat
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|Givinostat||See Plans and Pricing||Histone deacetylase inhibitors and methods for use thereof||REACTION BIOLOGY CORP. (Malvern, PA)||See Plans and Pricing|
|Givinostat||See Plans and Pricing||Anti-CS1 antibodies and antibody drug conjugates||AbbVie Biotherapeutics Inc. (Redwood City, CA)||See Plans and Pricing|
|Givinostat||See Plans and Pricing||Histone deacetylase 6 inhibition for enhancing T-cell function during anti-tumor response and tumor-peptide vaccination||H. Lee Moffitt Cancer Center and Research Institute, Inc. (Tampa, FL)||See Plans and Pricing|
|Givinostat||See Plans and Pricing||Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using GSK3 inhibitors: III||Frequency Therapeutics, Inc. (Woburn, MA)||See Plans and Pricing|
|Givinostat||See Plans and Pricing||Antiviral JAK inhibitors useful in treating or preventing retroviral and other viral infections||EMORY UNIVERSITY (Atlanta, GA)||See Plans and Pricing|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|Givinostat||World Intellectual Property Organization (WIPO)||WO2017030892||2035-08-14||See Plans and Pricing|
|Givinostat||Australia||AU2015339012||2034-10-31||See Plans and Pricing|
|Givinostat||Brazil||BR112017008945||2034-10-31||See Plans and Pricing|
|Givinostat||Canada||CA2966005||2034-10-31||See Plans and Pricing|
|Givinostat||European Patent Office||EP3212668||2034-10-31||See Plans and Pricing|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|